Will AI create more assets than pharma can absorb? AI is often discussed as a solution to pharmaceutical research and development productivity. It may be. Certainly Big Pharma thinks so,…
What is a "reach through? Let me paint the picture. Company A licenses technology to Company B. Company B then sublicenses to Company C. Under a reach-through provision, Company B…
After ~six months of integrating AI into our workflows at Lacerta Bio (plus building a few custom tools for ourselves and our clients), I've developed what I call the "intern-to-partner…
Introduction In Part I of this series, we introduced the idea that drug candidates emerging from artificial intelligence may have to be valued differently than those emerging from more traditional…
Introduction In Part I of this series, we introduced the idea that drug candidates emerging from artificial intelligence may have to be valued differently than those emerging from more traditional…
Introduction In Part I of this series, we introduced the idea that drug candidates emerging from artificial intelligence may have to be valued differently than those emerging from more traditional…
Ownership and Inventorship Ambiguity Introduction In Part I of this series, we introduced the idea that drug candidates emerging from artificial intelligence may have to be valued differently than those…
In America, we are adept at electing clowns and charlatans, and then ignoring or not bothering to understand what they are saying or doing. I blame this on our addictions…
A Five-Part Series on AI Drug Discovery Valuation Challenges Introduction I have no idea. That was my brilliant, insightful, memorable, put this on a t-shirt answer to the question posed…
Introduction Part I of this article proposed a framework to help guide the discussion around repurposing, which we define very broadly. Now, in Part II, we extend the framework and…